Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 344

1.

A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development.

Kashiwagi K, Furusyo N, Kubo N, Nakashima H, Nomura H, Kashiwagi S, Hayashi J.

J Infect Chemother. 2003 Dec;9(4):333-40.

PMID:
14691655
[PubMed - indexed for MEDLINE]
2.

Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.

Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kobayashi M, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kawamura Y, Kobayashi M, Kumada H.

J Med Virol. 2007 Oct;79(10):1485-90.

PMID:
17705189
[PubMed - indexed for MEDLINE]
3.

Long-term responders without eradication of hepatitis C virus after interferon therapy: characterization of clinical profiles and incidence of hepatocellular carcinoma.

Yabuuchi I, Imai Y, Kawata S, Tamura S, Noda S, Inada M, Maeda Y, Shirai Y, Fukuzaki T, Kaji I, Ishikawa H, Matsuda Y, Nishikawa M, Seki K, Matsuzawa Y.

Liver. 2000 Jul;20(4):290-5.

PMID:
10959807
[PubMed - indexed for MEDLINE]
4.

Clinical characteristics of patients with chronic hepatitis C showing biochemical remission, without hepatitis C virus eradication, as a result of interferon therapy. The Osaka Liver Disease Study Group.

Kasahara A, Hayashi N, Mochizuki K, Hiramatsu N, Sasaki Y, Kakumu S, Kiyosawa K, Okita K.

J Viral Hepat. 2000 Sep;7(5):343-51.

PMID:
10971822
[PubMed - indexed for MEDLINE]
5.

Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy.

Arase Y, Ikeda K, Tsubota A, Suzuki Y, Saitoh S, Kobayashi M, Suzuki F, Akuta N, Someya T, Hosaka T, Kobayashi M, Kumada H.

J Gastroenterol. 2004;39(5):455-60.

PMID:
15175944
[PubMed - indexed for MEDLINE]
6.

Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.

Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Koyama R, Hosaka T, Sezaki H, Kobayashi M, Kumada H.

Intervirology. 2007;50(1):16-23.

PMID:
17164553
[PubMed - indexed for MEDLINE]
7.

The incidence of hepatocellular carcinoma in patients with chronic hepatitis C after interferon treatment.

Miyajima I, Sata M, Kumashiro R, Uchimura Y, Ide T, Suzuki H, Tanikawa K.

Oncol Rep. 1998 Jan-Feb;5(1):201-4.

PMID:
9458322
[PubMed - indexed for MEDLINE]
8.

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K, Otani S.

Lancet. 1995 Oct 21;346(8982):1051-5.

PMID:
7564784
[PubMed - indexed for MEDLINE]
9.

Interferon beta 1a versus interferon beta 1a plus ribavirin for the treatment of chronic hepatitis C in Chinese patients: a randomized, placebo-controlled trial.

Han Q, Liu Z, Kang W, Li H, Zhang L, Zhang N.

Dig Dis Sci. 2008 Aug;53(8):2238-45. Epub 2007 Dec 13.

PMID:
18080763
[PubMed - indexed for MEDLINE]
10.

Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy.

Tokita H, Fukui H, Tanaka A, Kamitsukasa H, Yagura M, Harada H, Okamoto H.

J Gastroenterol Hepatol. 2005 May;20(5):752-8.

PMID:
15853990
[PubMed - indexed for MEDLINE]
11.

Comparison of thrice weekly vs daily human leucocyte interferon-alpha therapy for chronic hepatitis C. TVVH Study Group.

Chemello L, Cavalletto L, Bernardinello E, Boccato S, Casarin P, Cavinato F, Urban F, Pontisso P, Cecchetto A, Gatta A, Alberti A.

J Viral Hepat. 1999 Jul;6(4):321-7.

PMID:
10607247
[PubMed - indexed for MEDLINE]
12.
13.

Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C.

Toyoda H, Kumada T, Tokuda A, Horiguchi Y, Nakano H, Honda T, Nakano S, Hayashi K, Katano Y, Nakano I, Hayakawa T, Nishimura D, Kato K, Imada K, Imoto M, Fukuda Y; Yon-Ken HCV-HCC Follow-up Study Group.

J Viral Hepat. 2000 Nov;7(6):414-9.

PMID:
11115052
[PubMed - indexed for MEDLINE]
14.

Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection.

Furusyo N, Hayashi J, Ohmiya M, Sawayama Y, Kawakami Y, Ariyama I, Kinukawa N, Kashiwagi S.

Dig Dis Sci. 1999 Mar;44(3):608-17.

PMID:
10080158
[PubMed - indexed for MEDLINE]
15.

Effect of the dose and duration of interferon-alpha therapy on the incidence of hepatocellular carcinoma in noncirrhotic patients with a nonsustained response to interferon for chronic hepatitis C.

Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Hayashi K, Honda T.

Oncology. 2001;61(2):134-42.

PMID:
11528252
[PubMed - indexed for MEDLINE]
16.

The effect of retreatment with interferon-alpha on the incidence of hepatocellular carcinoma in patients with chronic hepatitis C.

Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, Sone Y, Hisanaga Y.

Cancer. 2000 Jan 1;88(1):58-65.

PMID:
10618606
[PubMed - indexed for MEDLINE]
17.

Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study.

Ikeda K, Marusawa H, Osaki Y, Nakamura T, Kitajima N, Yamashita Y, Kudo M, Sato T, Chiba T.

Ann Intern Med. 2007 May 1;146(9):649-56.

PMID:
17470833
[PubMed - indexed for MEDLINE]
18.

Analysis of background factors influencing long-term prognosis of patients with chronic hepatitis C treated with interferon.

Yoneyama K, Yamaguchi M, Kiuchi Y, Morizane T, Shibata M, Mitamura K.

Intervirology. 2002;45(1):11-9.

PMID:
11937766
[PubMed - indexed for MEDLINE]
19.

Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group.

Bernardinello E, Cavalletto L, Chemello L, Mezzocolli I, Donada C, BenvegnĂș L, Merkel C, Gatta A, Alberti A.

Hepatogastroenterology. 1999 Nov-Dec;46(30):3216-22.

PMID:
10626189
[PubMed - indexed for MEDLINE]
20.

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group.

Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, Iijima A, Urushihara A, Kiyosawa K, Okuda M, Hino K, Okita K.

Hepatology. 1998 May;27(5):1394-402.

PMID:
9581697
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk